SCHEMBL8044543

SCHEMBL8044543

Cc1cc(N)c(Cl)cc1NCCc1c[nH]c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.54
HTR1A P08908 4/20 0.54
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 1/20 0.54
HTT P42858 1/20 0.54
DRD2 P14416 3/20 0.54
HTR7 P34969 3/20 0.54
HTR6 P50406 3/20 0.54
CDK2 P24941 8/20 0.53
GPR84 Q9NQS5 1/20 0.49
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
SLC2A1 P11166 1/20 0.47
RAD52 P43351 1/20 0.47
KMT2A Q03164 1/20 0.47
MC5R P33032 1/20 0.47
MC3R P41968 1/20 0.47
MC1R Q01726 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8044595 0.86 HTR2A (0.53) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL8048447 0.80 CDK2 (0.51) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL8265777 0.79 ALDH1A1 (0.69) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL8041168 0.78 HTR2A (0.56) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL26978669 0.78 CDK2 (0.72) CDK2POLB
SCHEMBL17464549 0.77 CDK2 (0.55) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL8041585 0.77 POLB (0.59) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL18784064 0.77 KMT2A (0.59) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL18531442 0.76 ALDH1A1 (0.60) HTR2AHTR1AALDH1A1KDM4EHTT
SCHEMBL8048284 0.76 HTR2A (0.56) HTR2AHTR1AALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2023-02-21 US disclosed
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 JANSSEN PHARMACEUTICA NV (BE) 2020-04-23 US disclosed
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2017-04-27 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
WO-2009037308-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885HTR1A 2675/4885ALDH1A1 4139/4885
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885HTR1A 2675/4885ALDH1A1 4139/4885
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885HTR1A 2675/4885ALDH1A1 4139/4885
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 TP53, MDM2, TP53BP1 HTR2A 3587/4885HTR1A 2783/4885ALDH1A1 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.